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 Protein turnover is one of the most essential mechanisms controlling 
circadian rhythms. F-Box and Leucine Rich Repeat Protein21 (FBXL21) is a 
circadian E3 ligase which shows oscillatory mRNA transcripts and protein levels. 
It was previously found to perform subcellular compartment-specific E3 ligase 
activities targeting the core clock proteins CRYPTOCHROME(CRY)1/2. Here we 
identified a new sarcomeric target substrate, Telethonin(TCAP), which also shows 
circadian oscillation in its mRNA transcript and protein expression and, 
importantly, interaction with FBXL21 in an anti-phasic manner. Via computational 
and pharmacological tests, we identified Glycogen Synthase Kinase-3β(GSK-3β) 
as a regulator of FBXL21. Biochemical and molecular characterizations 
demonstrated that GSK-3β interacts with both FBXL21 and TCAP and affects Skp, 
Cullin1(Cul1), F-box containing (SCF) complex/E3 ligase-Substrate complex 
formation. Interestingly, GSK-3β knockdown significantly inhibited FBXL21-CUL11 
and FBXL21-TCAP complex formation. These results revealed a new circadian 
regulatory pathway that FBXL21 regulates TCAP via ubiquitin-mediated 
proteasomal pathway in the cytoplasm coordinatively with GSK-3β. 
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1.1  Introduction 
The ubiquitin proteasome system (UPS) is involved in post-translational regulatory 
mechanisms for circadian oscillation by controlling protein turnover throughout the circadian 
cycle (Stojkovic, Wing et al. 2014). Disruption of this system can cause severe physiological 
consequences such as neurodegenerative diseases and cancers (Welcker and Clurman 
2008; Frescas and Pagano 2008; Jin and Youle 2012). The UPS is comprised of serial 
enzymatic reactions of E1(ubiquitin-activating enzyme), E2(ubiquitin-conjugating enzyme) 
and E3(ubiquitin ligase) (Hershko, Heller et al. 1983). E1 activates ubiquitin molecule (Ub) in 
an ATP-dependent manners and activated Ub can form a thioester bond with E2. E2 plays a 
major role to determine the number of Ub molecules and chain linkage types which will poly-
ubiquitinate target proteins (Ye and Rape 2009). E3 ligases recognize and attach Ub to 
target proteins to regulate its level and activity. However, there are over 600 E3 ligases in 
the human genome that are not well studied (Deshaies and Joazeiro 2009), due to the 
transient nature of degradative ubiquitinated targets and typical weak interactions between 
E3 ligase and its substrate (Harper et al 2012). 
 
F-box domains mediate the formation of Skp1-Cul1-F-box protein (SCF) ubiquitin-
ligase complexes, containing Skp1, CULLIN, and F-box proteins for ubiquitin-mediated 
proteolysis (Kipreos and Pagano 2000). A catalytic core comprised of Cul1 and Rbx1 binds 
to F-box protein, which has at least one F-box motif, and Skp1, a substrate recognition (SR) 
module (Feldman et al., 1997; Kamura et al., 1999; Ohta et al., 1999; Seol et al., 1999). 
There are multiple ways to regulate E3 ligase activity at multiple levels. For example, when 
ubiquitin-like protein NEDD8 (neural-precursor-cell-expressed developmentally down-
regulated 8) conjugated to its target protein (Herrmann J et al. 2007), this needdylation at 
the c-terminus of Cul1 increases SCF E3 ligase activity by inducing a structural 
rearrangement in its backbone (Lydeard, Schulman et al. 2013), while F-box proteins serve 
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as a receptor that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex 
(Skowyra et al., 1997). In contrast to the molecular mechanisms that regulate F-box protein 
function, upstream cellular signaling for most F-box proteins in SCF complex formation and 
E3 ligase activation remains largely unclear. 
 
It was previously reported that the E3 ligase FBXL3 and its paralogue FBXL21 exert  
spatiotemporal regulation on the degradation of the circadian transcription repressor  
CRYPTOCHROMEs (CRY). In the nucleus, FBXL3 is an active E3 ligase and degrades 
CRY, but FBXL21 plays an antagonistic role and protects CRY from degradation by 
sequestering CRY from FBXL3. However, in the cytoplasm, FBXL21 is the active E3 ligase 
and degrades CRY. FBXL21 level itself is under circadian control, peaking at subjective 
night while FBXL3 expresses constitutively (Yoo et al 2013). While regulation of FBXL21 
activity is largely unknown, previous studies of E3 ligases have highlighted an important role 
of phosphorylation of both E3 ligases and substrates in ubiquitin-mediated proteasomal 
degradation (Gao, Inuzuka et al., 2009, Lin, Wang et al., 2009, Kazlauskaite, Kelly et al. 
2014, Filipcik, Curry et al. 2017). 
 
Increasing evidence indicates that muscle structure and physiology are subjected to 
clock regulation (Podobed et al 2014; Moreira et al 2000). It was reported that there are 
muscle-specific clock-controlled genes that are regulated by the core clock and perform 
important physiological functions in skeletal muscle. For example, Myogenic Differentiation 
1(MyoD1) is regulated by Clock and Bmal1, genetic disruption of each gene, namely Clock 
(Δ19) and Bmal1(-/-), leads to defects in structure as well as function of skeletal muscle in 
mice (Andrews et al 2010). 
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Through yeast 2-hybrid screening using a mouse muscle expression library, our lab 
identified a sarcomere protein Telethonin, also known as Titin cap or TCAP as a new 
substrate for FBXL21. TCAP is 19kDa cytoplasmic protein expressed exclusively in the 
cardiac and skeletal muscle. TCAP interacts with titin through its N-terminal β-sheet to 
anchor titin to the Z-disc (Gregorio, Trombitas et al. 1998, Mues, van der Ven et al. 1998, 
Pinotsis, Petoukhov et al. 2006). It is one of the most abundant transcripts in striated muscle 
(Valle, Faulkner et al. 1997). Interestingly, previous studies reported that TCAP is 
transcriptionally regulated by the circadian clock (Podobed et al 2014). Clinically it is 
reported when the c-terminal of Tcap was affected by particular mutations, sarcomeric 
structure of skeletal muscle is potentially affected then induces physiological defects such 
as weakened muscle, muscle hypertrophy as well as elevated serum creatine-kinase levels 
(Moreira et al 2000). 
 
 With TCAP as a newly identified substrate of FBXL21, we are expecting to elucidate 
the mechanism of cytoplasm specific E3 ligase activity of FBXL21 as well as a new circadian 












1.2 Central hypothesis and specific aims 
We hypothesize that FBXL21 is the main E3 ligase for cytoplasmic TCAP 
degradation in a circadian manner through a phosphorylation-dependent regulatory 
mechanism. 
 
Specific Aim 1: To determine the circadian interaction between FBXL21 and TCAP in vivo.  
Published and preliminary results strongly suggest a circadian pattern of FBXL21-TCAP  
interaction. We will collect skeletal muscle tissues throughout the Zeitgeber time course 
(ZT 0, 4, 8, 12, 16, 20) from wild-type mice, and perform reciprocal co-immunoprecipitation  
and immunoblotting with TCAP and FBXL21 antibodies respectively.  
 
Specific Aim 2: To map TCAP ubiquitination sites and investigate whether mutant TCAP will 
be resistant to FBXL21-mediated degradation. We will mutate 5 TCAP lysine sites to 
arginine which is structurally inactive for ubiquitination. It is expected that mutation of the  
ubiquitination sites will result in attenuated protein degradation by FBXL21, and this can be  
confirmed from protein half-life measurement using cycloheximide (CHX). 
 
Specific Aim 3: To screen candidate kinases involved in regulatory phosphorylation and 
investigate its function in the FBXL21-TCAP interaction. Using a pharmacological approach, 
we will screen 5 candidate kinases. We will employ half-life and bimolecular fluorescence 
complementation assays to assess kinase function in TCAP degradation, FBXL21-SCF 
complex formation, and FBXL21-TCAP interaction. 
 
Our study will demonstrate a regulatory pathway underlying circadian TCAP 
degradation by FBXL21. These experiments will elucidate a novel mechanism delineate the 




























2.1 Mouse strains and tissue collection 
C57BL/6J (Stock # 000664) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). All mice were group-housed and maintained under Light-Dark: LD 12:12 
conditions (transferred to constant darkness: DD only if needed) with food and water 
provided ad libitum. All animal care and procedures were approved by the Animal Care and 
Use Committee of the University of Texas Health Science Center in Houston.   
             C57BL/6J mice were maintained in LD 12:12 and then moved to constant darkness 
(DD) 36 hours prior to tissue collection. Mice were euthanized by cervical dislocation under 
infrared lights at ZT (Zeitgeber Time) 0, 4, 8, 12, 16 and 20. Gastrocnemius, tibialis anterior, 
and quadriceps were harvested under normal white light. Tissues were sectioned, snap-
frozen on dry ice, then transferred to pre-chilled 1.5mL micro-centrifuge tubes to prevent 
proteasomal degradation. Samples were stored in -80°C prior to further experiments.  
 
2.2 Protein extractions 
  Frozen tissues were immersed in 300uL of cold extraction buffer, chopped with 
scissors and homogenized with an electric homogenizer for 2 seconds. Then added 200uL 
of cold extraction buffer and vortexed at 3000rpm for 30 seconds every 5 minutes for a total 
20 minutes for full disruption. Samples were then centrifuged at 13000rpm for 20minutes at 
4°C. Supernatants were transferred to new pre-chilled 1.5mL tubes. Bradford Assay was  
performed to quantify as described (Bradford MM. 1976). After measuring optical density of 
each samples at 595nm on the Tecan plate reader, lysates were diluted with extraction 
buffer to 300uL with 1.5μg/uL concentration.  
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2.3 Immunoprecipitations and Immunoblotting 
For immunoblotting, 20uL were aliquoted into a new tube with 5x Laemmli loading 
buffer and stored in -20°C for further processing. For immunoprecipitation, lysates were 
hybridized with Guinea Pig IgG conjugated with anti-FBXL3(generated as specified in Yoo et 
al 2013), Rabbit IgG conjugated with anti-FBXL21 (generated as specified in Yoo et al 
2013), and Mouse IgG conjugated with anti-TCAP (BD Biosciences) respectively. 10ug of 
muscle lysates as well as IgG-pulled down samples were resolved by SDS-PAGE and 
Western Blotting analysis. Antibodies were used from 1:1000 to 1:3000. Relative protein 
abundance was quantified using ImageJ. Two-way ANOVA was performed to measure 
differences between TCAP and FBXL21. Bonferroni’s multiple comparison test was used to 
compare among zeitgeber time points using GraphPad Prism (GraphPad Software, La Jolla 
California USA). Error bars represent the standard error of the mean (SEM) for each time 
point from three independent replicates. 
 
2.4 Plasmids and Mutagenesis 
 FBXL3 and FBXL21 cDNA was synthesized as specified in Yoo et al (2013). Full-
length Fbxl21 in pCMV10-3XFlag (Sigma) was used to generate mutant forms of Fbxl21. 
PCR-based site-directed mutagenesis was performed to generate each mutant (Table 1). 
 
2.5 Cell culture and Transfection 
293T cell line (ATCC CRL-3216) was cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin.  
For TCAP degradation assay, cells were plated onto 12well plates with 1.5x105 
24hours in advance then transfected with indicated constructs using iMFectin (GenDepot).  
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For bimolecular fluorescence complementation assay, glass covers were coated with 
poly-L-Lysine prior to cell seeding. 2x105 cells were plated onto 6well plates 24 hours prior 
to transfection.  
 
2.6 TCAP degradation assay 
Media were replaced 16 hours after transfection. 36 hours after transfection, cells 
were treated with 100μg/mL of cycloheximide (CHX) for 0, 2, 4, and 6 hours.  At the end of 
each indicated treatment time, 293T cells were washed with PBS, pelleted and stored in -
80°C until further process. Half-life parameter K was calculated using one-phase decay. 
Statistical difference between half-life parameter K was calculated by one-way ANOVA. 
Error bars represent ± SEM (n=3). 
 
2.7 Bimolecular Fluorescence Complementation (BiFC) assay 
 To observe in vitro localization of SCF complex as well as ligase-substrate complex,  
we employed the bimolecular fluorescence complementation (BiFC) assay as previously 
described (Kerppola 2006). PCR amplified TCAP cDNA was cloned into KpnI and BamHI 
sites of VenC. VenN-TCAP or VenN-Fbxls and VenC-Skp1 or VenC-Cullin were transfected 
into 293T cells using the iMFectin (GenDepot). GSK-3β shRNA (pLKO.1-GSK-3β-1: 
Addgene 32496, pLKO.1-GSK-3β-2: Addgene 32497) were co-transfected as indicated.  
Cells were fixed with 4% paraformaldehyde in PBS for 15 min. Samples were stained 
with DAPI (1μg/ml), washed twice, immersed with PBS and sealed with top-seal A 
membrane (Perkin-Elmer). Fluorescence images were acquired on a Axiocam 506 mono 
(Carl Zeiss) equipped with an inverted 63x 0.45NA UPLFL objective on an Axio Imager M2 
Upright Microscope (Carl Zeiss). Seven locations in each slide were selected. Images were 
taken in the channel sequence of FITC (Ex 493, Em 528), and DAPI (Ex 390, Em 435) filter 
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sets. For quantification of BiFC results, original image files were imported to ImageJ (NIH) 
and signal was quantified by. Briefly, cytoplasms were recognized based on FITC 
fluorescence (regions with no fluorescence considered as background) and corrected total 
cell fluorescence (CTCF) was calculated by integrated density. About 100 cells were 
identified and measured in each image, and the average values of cells in one image were 
obtained for further normalization and statistical analysis. Seven images from each slide 
were averaged and the experiments were replicated three times. 
 
2.8 Statistical analysis 
All statistical analysis was performed in GraphPad Prism (Version 8). Results are 
presented as mean ± SEM unless otherwise stated. Data were analyzed using student’s t-
test, one-way ANOVA followed by post-hoc analysis using Dunnett's multiple comparison 
test or two-way ANOVA followed by post-hoc analysis using Bonferroni test. A value of P < 














Table 1. Site-directed Mutagenesis primers 
Flag-TCAP K26R Forward CTTCTGGGCTGAGTGGAGAGACCTGACTCTGTCTA 
Flag-TCAP K26R Reverse TAGACAGAGTCAGGTCTCTCCACTCAGCCCAGAAG 
Flag-TCAP K98R Forward CATCTTCACGCCCACCAGGGTGGGGGCCTCCAAGG 
Flag-TCAP K98R Reverse CCTTGGAGGCCCCCACCCTGGTGGGCGTGAAGATG 
Flag-TCAP K103R Forward CAAGGTGGGGGCCTCCAGGGAGGAGCGCGAGGAGA 
Flag-TCAP K103R Reverse TCTCCTCGCGCTCCTCCCTGGAGGCCCCCACCTTG 
Flag-TCAP K138R Forward CGTGGCTGAGATCACAAGGCAGCTTCCCCCTGTGG 
Flag-TCAP K138R Reverse CCACAGGGGGAAGCTGCCTTGTGATCTCAGCCACG 
Flag-TCAP K148R Forward GTGCCAGTCAGCAGACCCGGGCCCCTG 












































3.1 Circadian time dependent TCAP-FBXL21 interaction with anti-phasic expression 
Preliminary experiments with ectopic expressions of FBXL3, FBXL21 and TCAP in  
293T cells showed that both FBXL3 and FBXL21 interact with TCAP (Figure 1A). However,  
FBXL21 dose-dependently destabilized TCAP which suggests that FBXL21 plays as the  
primary E3 ligase for TCAP (Figure 1B). Considering a strict localization of TCAP (Valle, 
Faulkner et al. 1997) and cytoplasm-specific E3 ligase function of FBXL21(Hirano, 
Yumimoto et al. 2013, Yoo, Mohawk et al. 2013) together, we hypothesize that FBXL21 will 
form a complex with TCAP prior to the degradation of TCAP in a circadian time-dependent 
manner. Co-immunoprecipitation was performed using gastrocnemius muscle collected from 
WT C57BL/6 mice during a circadian cycle under 12hr:12hr light:dark (LD) cycle.  
 
 We observed oscillatory expressions of FBXL21 and TCAP in an anti-phasic manner 
(Figure 2A). TCAP peaks at ZT8 and ZT12 while FBXL21 peaks at ZT0,4 and ZT16,20, 
whereas FBXL3 shows constitutive expression as previously reported (Yoo et al 2013).  
Proteins expression shows significant statistical difference via Two-way ANOVA (p < 
0.0001). Bonferroni’s multiple comparison test shows significant difference at ZT16 (p < 
0.05) and ZT20 (p < 0.01) (Figure 2B). Interestingly, this anti-phasic expression reflects 
robust TCAP-FBXL21 circadian interaction which occurs strongly at ZT0 and ZT4, suggest 
that FBXL21-mediated circadian proteasomal TCAP degradation. Whereas FBXL3 did not 
show any significant interaction with TCAP throughout the circadian cycle presumably due 
to the localization of TCAP (strict cytoplasmic) and FBXL3 (dominantly nuclear) (Siepka, 
Yoo et al. 2007) (Figure 2C). This result suggests that FBXL21-mediated circadian 
proteasomal degradation of TCAP contributes to the robust TCAP protein oscillation, in 
addition to the rhythmic tcap transcript levels as previously reported (Podobed, Alibhai et al. 















Figure 1. Identification of TCAP as a substrate of FBXL21 in vitro 
(A) Interaction of FBXL3 and FBXL21 with TCAP. 293T cells were transfected with Flag-
Fbxl3, Flag-Fbxl21 and HA-TCAP and immunoprecipitation were performed using anti-Flag 
antibody (M2). Co-immunoprecipitated proteins were analyzed by Immunoblotting with anti-
HA antibody. (B) FBXL21 but not FBXL3 decreases TCAP amount in a dose-dependent 
manner. 293T cells were co-transfected with indicated constructs. 32 hours after 
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Figure 2. Identification of TCAP as a substrate of FBXL21 in vivo  
(A) FBXL21 showed anti-phase oscillation with TCAP in skeletal muscle. (B) quantification of 
TCAP and FBXL21. Error bars represent ±SEM for each time point from three independent 
replicates. Two-way ANOVA shows significant statistical difference between TCAP and 
FBXL21 (p < 0.0001). Bonferroni’s multiple comparison test shows significant difference at 
ZT16 (p < 0.05) and ZT20 (p < 0.01).  (C) co-immunoprecipitation using FBXL3, FBXL21, 






















0 4 8 12 16 20 IgG 
0 4 8 12 16 20 IgG 
B C 
 16 
3.2 Identification of TCAP ubiquitination lysine sites by FBXL21 
 Preliminary experiments validated that FBXL21 degrades TCAP via ubiquitin-
mediated pathway by showing blocked TCAP degradation with MG132(10μg/mL), a 
proteasome inhibitor treatment (Figure 3A). Through ubiquitination assay with MG132 
treatment(10μg/mL), it was observed that co-expression of FBXL21 results to enriched poly-
ubiquitinated TCAP compared to TCAP expression itself (Figure 3B) which enabled us to 
conclude that FBXL21-mediated TCAP degradation is mediated by ubiquitination-dependent 
proteasomal degradation. With these results, we sought for the ubiquitination sites on TCAP 
required for its degradation.  
 
 There are 5 lysine sites in TCAP (K26, K98, K103, K138, and K148), so first, each of 
them was converted to arginine individually which is structurally inactive form for 
ubiquitination (Figure 4A) (Xu and Jaffrey 2014).  An endpoint degradation assay was 
performed with FBXL21 co-expression to see whether mutant TCAPs show attenuated 
degradation compare to WT. From a primary screen, K26R and K98R mutations conferred 
relative resistance to FBXL21-mediated TCAP degradation (Figure 4B). Then we generated 
K26R/K98R mutant and perform CHX chasing assay with FBXL21 co-expression and found 
this mutant form shows a significant reduced degradation rate (Half-life: TCAP: 5.549, 
TCAP/FBXL21: 2.299, TCAPK26R/K98R: 19.45, TCAPK26R/K98R /FBXL21: 9.408 hours) 
 compare to WT TCAP (Figure 4C). This result indicates that FBXL21 targets K26 and K98 












Figure 3. TCAP degradation via ubiquitin-mediated proteasomal pathway 
(A) MG132 inhibited TCAP degradation by FBXL21. 293T cells were co-transfected with 
indicated constructs, 30 hours later cells were treated with MG132 (10μg/ml) for 6 hr. Cells 
were harvested and subjected to Immunoblotting with indicated antibodies. Right panel: 
Real-time RT-PCR analysis of hFbxl21 mRNA expression (*, p < 0.05) (B) 293T cells were 
transfected with indicated constructs. Cells were treated with MG132 (10μg/ml) 6 hours 
before harvest. Cell lysate were immunoprecipitated with Flag antibody and Immunoblotting 




























+ + + + + 
+ - - - - 
 18 
Table 2. Lysine sites on TCAP 
Telethonin, Mus musculus 
 
                                                               26 
MATSELSCQVSEENQERREAFWAEWKDLTLSTRPEEGCSLHEEDTQRHETYHRQ 
                                                                                                      98        103 
GQCQAVVQRSPWLVMRLGILGRGLQEYQLPYQRVLPLPIFTPTKVGASKEEREETP 





































Figure 4. K26R/K98R are ubiquitinated sites on TCAP 
(A) The five lysine sites in TCAP were individually mutated to arginine and stability of each K 
to R mutant was examined by co-transfecting Fbxl21 expression construct into 293T cells. 
(B) 293T cells were co-transfected with indicated constructs. 32 hours after transfection, 
cells were treated with 40 μg/ml CHX and incubated for the indicated time before harvest. 
Immunoblotting was performed to detect TCAP, FBXLs levels using anti-Flag antibody. (C) 
Quantification of the effect of FBXL21 on wild type TCAP and K26R/K98R stability. Error 
bars represent mean ±SEM (n=3). Half-life was determined by using nonlinear, one-phase 
decay analysis (Half-life: TCAP: 5.549, TCAP/FBXL21: 2.299, TCAPK26R/K98R: 19.45, 
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3.3 GSK-3β regulates FBXL21-TCAP and FBXL21-SCF complex formation 
We identified that a sacromere protein TCAP is regulated via FBXL21-mediated 
ubiquitin proteasomal pathway, and TCAP has 2 lysine sites which can be regulated by 
ubiquitin. However, upstream signaling for F-box proteins, such as FBXL21, remains 
unstudied. As there are previous studies revealed regulatory phosphorylation in both 
substrates and E3 ligase (Gao, Inuzuka et al. 2009, Lin, Wang et al. 2009, Kazlauskaite, 
Kelly et al. 2014, Filipcik, Curry et al. 2017), we were trying to examine the upstream 
regulatory mechanism for FBXL21.  
 
First, we screened putative phosphorylation sites of FBXL21 using phosphoScan, 
NetPhos3.1(Blom, Sicheritz-Ponten et al. 2004) which resulted to 5 candidate kinases with 
relatively high scores (> 0.45); GSK-3; DNA-PK; CDK; PKC; and CK1. We performed a 
pharmacological assay using specific inhibitors for each kinase (CHIR99021: GSK-3 
inhibitor, NU7441: DNA-PK inhibitor, Ro3306: CDK inhibitor, Sotrastaurin: PKC inhibitor, 
IC261: CK1 inhibitor) to figure out protein degradation effect and found CHIR99021, a pan-
GSK-3 inhibitor, shows strongly repressed FBXL21 mediated TCAP degradation (Figure 
5A). However, since GSK-3β, not GSK-3α, is known for an essential role in muscle (van der 
Velden, Schols et al. 2008, Verhees, Schols et al. 2011, Beurel, Grieco et al. 2015), we 
focused on GSK-3β for sarcomere protein, TCAP degradation.  
 
Second, we performed co-immunoprecipitation to see whether GSK-3β can interact 
with both FBXL21 and/or TCAP. With co-expression of GSK-3β, both FBXL21 and TCAP 
can be pulled down (Figure 5B), suggesting they both can be substrates of GSK-3β.  
 
Therefore, we sought for a GSK-3β regulation role on FBXL21-TCAP and FBXL21-
SCF complex formation so employed the bimolecular fluorescence complementation (BiFC) 
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assay as previously described (Kerppola 2006). Split N-, C-terminal venus fluorescence 
constructs were respectively fused to Fbxl21 (results to VenN-Fbxl21) and Tcap (results to 
VenC-Tcap). Split form of Venus itself cannot emit fluorescence, however, expression of 
constructs was confirmed through Western Blotting assay (Figure 7A, 7B). VenN-FBXL21 
and VenC-TCAP interacts in the cytoplasm measured at the Venus emission wavelength 
(528nm). With GSK-3β shRNA co-expression, we were able to observe significantly 
decreased fluorescence intensity which suggests GSK-3β knockdown inhibits FBXL21-
TCAP complex formation (Figure 6A).  
 
To investigate the upstream regulatory mechanism of FBXL21, next we utilized 
components of SCF complex to examine a role of GSK-3β. First, VenC-CUL1 was used as 
previously reported (Yoo, Mohawk et al. 2013) whose expression was validated through 
Western Blotting assay (Figure 7B). FBXL21 and CUL1 forms complex in the cytoplasm 
primarily and this interaction was significantly impaired with GSK-3β shRNA co-expression 
(Figure 6B) which suggests GSK-3β might mediate FBXL21 phosphorylation that leads to 
FBXL21 activation and SCF complex formation regulation. VenC-SKP1 was used to seek 
whether a default state of SCF complex can also be regulated by GSK-3β. VenC-SKP1 
expression was also confirmed through Western Blotting assay (Figure 7C). Interestingly, 
FBXL21-SKP1 complex formation was not affected by GSK-3β knockdown (Figure 6C). 
Together, it was able to deduce that the regulatory role of GSK-3β applies to FBXL21-CUL1 
complex formation, which is an example of active stage of SCF complex (F-box protein-
CUL1), but not to FBXL21-SKP1 complex formation, an example of default state of SCF 








Figure 5. GSK-3β regulates FBXL21-mediated TCAP degradation 
(A) 293T cells were co-transfected with indicated constructs. 12 hours after transfection, 
cells were treated with indicated kinase inhibitors for 24 hours before CHX treatment. 
Immunoblotting were performed to detect TCAP and FBXL21. (B) Interaction of TCAP and 
FBXL21 with GSK-3β. 293T cells were transfected with Flag-TCAP, Flag-Fbxl21 and HA-
GSK-3β and immunoprecipitation were performed using anti-Flag antibody (M2). Co-






Figure 6. FBXL21-TCAP and SCF complex formation regulated by GSK-3β 
(A) TCAP and FBXL21 form complex in the cytoplasm and shGSK-3β co-transfection 
inhibited complex formation. Right panel: bar graph shows the mean ±SEM of quantification 
of BiFC signal from three replicate experiments. One-way ANOVA shows the relative 
fluorescence intensity shows significant statistical difference between mock and GSK-3β 
shRNA. (***, p < 0.0001). (B) FBXL21-CULLIN1 complex formation was significantly 
inhibited by shGSK-3β co-transfection. Right panel: bar graph show the mean ±SEM of 
quantification of BiFC signal from three replicate experiments. One-way ANOVA shows 
significant statistical difference between mock and GSK-3β shRNA (****, p < 0.0001). (C) 
FBXL21-SKP1 complex formation was not affected by shGSK-3β co-transfection. Right 
panel: bar graph shows the mean ±SEM of quantification of BiFC signal from three replicate 











Figure 7. Expression validation of Venus-fused constructs 
293T cells were co-transfected with indicated constructs. (A) VenC-TCAP expression 
validation. 32 hours after transfection, MG132(10μg/mL) was treated 5hours prior to cell 
harvest. Immunoblotting was performed to detect TCAP (B) VenN-FBXL21 and VenC-CUL1 
expression validation. 32 hours after transfection, cells were harvested. Western blotting 
was performed to detect CUL1 and FBXL21. (C) VenC-SKP1 expression. 32 hours after 



































4. Discussion  
 Ubiquitin-mediated proteasomal degradation plays an essential role in regulation at 
the protein level (Stojkovic, Wing et al. 2014). Previously, two paralogous E3 ligases, FBXL3 
and FBXL21, were reported to play antagonistic roles depend on localization onto core clock 
protein CRY. We focused on FBXL21 due to its interesting localization-specific function; 
specifically, FBXL21 protects CRY in the nucleus but degrades CRY in the cytoplasm (Yoo, 
Mohawk et al. 2013). The current project aims to further investigate cytoplasm-specific 
regulatory function of FBXL21. 
 
 Through yeast 2-hybrid assays, TCAP was identified as a new target substrate for 
FBXL21. Muscle structure and physiology have been studied in terms of clock regulation 
(Podobed et al 2014; Moreira et al 2000) with evidence showing correlation between 
muscle-specific clock controlled genes and physiological impairments structurally and 
functionally (MacLellan et al 2005; Andrews et al 2010; Shavlakadze et al 2013; Podobed et 
al 2014; Harfmann et al 2015; Mayeuf-Louchart et al 2015). As TCAP strictly exists in the 
cytoplasm and both FBXL21 and TCAP transcripts levels oscillate throughout the circadian 
cycle, TCAP was thought to be a good molecule to study localization specific FBXL21 
activity. 
 
 Here we showed that the circadian E3 ligase FBXL21 interacts with TCAP in an anti-
phasic manner consistent with their protein expression patterns. We further demonstrated 
that the degradation of TCAP was conferred by ubiquitin-mediated proteasomal pathway. 
Using TCAP mutant forms, we were able to pinpoint sites responsible for ubiquitination. 
Among the 5 lysine sites, K26 and K98 were found to be responsible for TCAP ubiquitination 
and TCAP with a missense mutation on each of these sites showed attenuated degradation 
even in the presence of FBXL21.  
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We sought to understand regulatory mechanisms of FBXL21 activity and examined a 
possible crosstalk between ubiquitination and phosphorylation (Gao and Karin et al 2005). 
Phosphorylation can regulate ubiquitination of protein via multiple mechanisms; in particular, 
it has been reported that phosphorylation can influence ubiquitination by regulating 
substrate/ligase interaction at the level of subcellular compartmentalization (Hunter 2007). 
Through multiple steps of screening, we identified GSK-3β as a kinase interacting with both 
FBXL21 and TCAP. Previously, protein kinase D(PKD), thymidine kinase(TK), and Ca2+-
Calmodulin-dependent Kinase II(CaMK) was reported to phosphor-regulate TCAP in cardiac 
myocytes (Gautel 2011, Candasamy et al. 2013) while none of kinases have been reported 
for FBXL21. By employing BiFC assays to directly visualize protein complexes within cells, 
we determined that not only substrate/ligase complex formation but also SCF complex 
formation itself can be regulated by GSK-3β. Taken together, experiments aforementioned 
support our hypothesis by showing a novel mechanism involving GSK-3β mediated co-
phosphorylation of a circadian E3 ligase and its cytoplasmic target substrate. Our future 
experiments will aim to elucidate deeper regulatory mechanisms as well as physiological 
functions of FBXL21 regulation by GSK-3β in muscle physiology.  
 
 TCAP has been studied in relevance to diseases such as Limb-girdle muscular 
dystrophy and dilated cardiomyopathy (Knoll, Hoshijima et al. 2002, Hershberger, Parks et 
al. 2008, Markert, Meaney et al. 2010, Hirtle-Lewis, Desbiens et al. 2013, Francis, Sunitha 
et al. 2014, Chamova, Bichev et al. 2018).  Previously, other E3 ligases such as 
MDM2(Mouse double minute 2 homolog) and MuRF1/2(Muscle RING Finger1) have been 
found to interact with TCAP. However, MDM2 and MuRF1/2 showed indirect or 
unsubstantiated degradation mechanisms related to TCAP (Witt, Granzier et al. 2005, Tian, 
Li et al. 2006, Witt, Witt et al. 2008). In comparison, our study shows FBXL21 as a direct E3 
ligase responsible for TCAP proteasomal degradation. On-going experiments will reveal 
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further regulatory post-translational modification on TCAP to understand its stability for 
proper structure and function maintenance. Cardiac TCAP has been shown to interact with 
PKD in terms of maintaining transverse tubule organization and intracellular Ca2+ transients 
in myocytes (Mayans, van der Ven et al. 1998, Candasamy, Haworth et al. 2014); however, 
PKD selective inhibitor did not affect TCAP phosphorylation (Candasamy, Haworth et al. 
2014). This suggests that there may be additional kinases, potentially GSK-3β, involved in 
TCAP phosphorylation.  
 
According to previous studies, GSK-3β has been shown to phosphorylate five core 
clock proteins including PER2, CRY2, CLOCK, BMAL1 and REV-ERBα (Yin, Wang et al. 
2006, Kaladchibachi, Doble et al. 2007, Spengler, Kuropatwinski et al. 2009, Kurabayashi, 
Hirota et al. 2010, Sahar, Zocchi et al. 2010). Previous studies emphasized an importance 
of the UPS system in GSK-3β regulated muscle protein turnover. However, GSK-3 regulated 
E3 ligase activity and the molecular mechanism of myofibrillar protein degradation have not 
been reported. As our results unveiled an involvement of GSK-3β mediated regulation of a 
circadian E3 ligase important for SCF complex formation and FBXL21-substrate complex 
formation, the FBXL21-GSK-3β axis represents a novel circadian regulatory pathway with a 
broad physiological function and cellular targets.  
 
In conclusion, my work has demonstrated that TCAP is a bona fide cytoplasmic 
substrate of the circadian E3 ligase FBXL21. GSK-3β was found to phosphorylate both 
FBXL21 and TCAP to regulate SCF and FBXL21-TCAP complex formation. Our findings 
therefore establish FBXL21-GSK-3β as a novel circadian regulatory axis that controls 
accumulation of a key sarcomere component in skeletal muscle and suggest a broad 
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